Emerging med-tech Novadaq Technologies (NASDAQ:NVDQ) is now entering a new phase of its corporate life. The soured relationship with LifeCell
is now in the company's past, and Novadaq is moving forward with a
suite of products that offered demonstrated clinical benefits.
Transitioning back from LifeCell is going to have a near-term impact on
sales, though, and not for the good. Longer-term, I continue to believe
that Novadaq can generate more than $1 billion in annual revenue with a
portfolio of products that drive better outcomes in open surgery,
minimally invasive surgery, and wound care.
Click here to read more:
Look Past A Sales Transition To Novadaq's Future
No comments:
Post a Comment